Format

Send to

Choose Destination
J Drugs Dermatol. 2015 Mar;14(3):244-53.

Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition.

Abstract

Advances in the understanding of the pathogenesis of psoriasis have led to the development of biologic agents that target T cells and cytokines that play a specific role in the underlying inflammation associated with psoriasis (eg, tumor necrosis factor-α inhibitors, interleukin [IL]-12/23 inhibitors). In this review, evidence for the central role of IL-17 in the pathophysiology of psoriasis is presented, along with available clinical trial data on the selective IL-17 inhibitors in development. Three biologic agents that target IL-17 are currently in clinical development: secukinumab, ixekizumab, and brodalumab. Clinical studies to date suggest a favorable safety profile and the potential for better efficacy over the previous generation of agents, with Psoriasis Area Severity Index 75 response rates of up to 80% or greater. Fully published results of phase III studies of these agents are eagerly awaited.

PMID:
25738846
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for SanovaWorks
Loading ...
Support Center